Prostate Cancer Stocks List



Recent Signals

Date Stock Signal Type
2021-02-25 ABBV Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-25 ADMP Stochastic Reached Oversold Weakness
2021-02-25 ADXS Fell Below 20 DMA Bearish
2021-02-25 AEZS Narrow Range Bar Range Contraction
2021-02-25 AFMD Lower Bollinger Band Walk Weakness
2021-02-25 AYTU 20 DMA Resistance Bearish
2021-02-25 BLCM 20 DMA Resistance Bearish
2021-02-25 BNR Upper Bollinger Band Walk Strength
2021-02-25 BNR Calm After Storm Range Contraction
2021-02-25 CBLI Calm After Storm Range Contraction
2021-02-25 CRDF Lower Bollinger Band Walk Weakness
2021-02-25 EDAP Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-25 EDAP 1,2,3 Pullback Bullish Bullish Swing Setup
2021-02-25 ENDP 1,2,3 Pullback Bullish Bullish Swing Setup
2021-02-25 ENDP MACD Bearish Signal Line Cross Bearish
2021-02-25 ENDP Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-25 EPIX MACD Bearish Signal Line Cross Bearish
2021-02-25 EXEL Bollinger Band Squeeze Range Contraction
2021-02-25 EXEL Fell Below 200 DMA Bearish
2021-02-25 EXEL Fell Below 50 DMA Bearish
2021-02-25 EXEL Fell Below 20 DMA Bearish
2021-02-25 EXEL Bearish Engulfing Bearish
2021-02-25 HARP 50 DMA Resistance Bearish
2021-02-25 HARP Lower Bollinger Band Walk Weakness
2021-02-25 IONS Fell Below 200 DMA Bearish
2021-02-25 ISR 50 DMA Support Bullish
2021-02-25 JAZZ Jack-in-the-Box Bullish Bullish Swing Setup
2021-02-25 JAZZ Calm After Storm Range Contraction
2021-02-25 MYGN Shooting Star Candlestick Bearish
2021-02-25 MYGN New 52 Week High Strength
2021-02-25 MYGN Bollinger Band Squeeze Range Contraction
2021-02-25 MYGN Lizard Bearish Bearish Day Trade Setup
2021-02-25 MYOV Bollinger Band Squeeze Range Contraction
2021-02-25 NUVB Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-02-25 NUVB 20 DMA Support Bullish
2021-02-25 NUVB NR7 Range Contraction
2021-02-25 NUVB Stochastic Reached Overbought Strength
2021-02-25 NYMX Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-25 NYMX Fell Below 20 DMA Bearish
2021-02-25 NYMX Fell Below 200 DMA Bearish
2021-02-25 NYMX 1,2,3 Pullback Bullish Bullish Swing Setup
2021-02-25 OPK Lower Bollinger Band Walk Weakness
2021-02-25 PDSB Fell Below 20 DMA Bearish
2021-02-25 PROF Lower Bollinger Band Walk Weakness
2021-02-25 SLRX Calm After Storm Range Contraction
2021-02-25 SLRX Fell Below 20 DMA Bearish
2021-02-25 SNY Stochastic Buy Signal Bullish
2021-02-25 SNY Expansion Breakdown Bearish Swing Setup
2021-02-25 SNY 180 Bearish Setup Bearish Swing Setup
2021-02-25 SPPI MACD Bearish Signal Line Cross Bearish
2021-02-25 SPPI 180 Bearish Setup Bearish Swing Setup
2021-02-25 SPPI Bollinger Band Squeeze Range Contraction
2021-02-25 SPPI Fell Below 20 DMA Bearish
2021-02-25 SPPI 200 DMA Resistance Bearish
2021-02-25 VERU Fell Below 20 DMA Bearish

Recent News for Prostate Cancer Stocks

Date Stock Title
Feb 26 EXEL European Medicines Agency's CHMP Backs Approval Of Cabometyx/Opdivo Combo In Kidney Cancer
Feb 26 AMGN AstraZeneca and Amgen's tezepelumab successful in phase 3 for severe asthma
Feb 26 ABBV Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout
Feb 26 AMGN AstraZeneca-Amgen drug could widen treatment options for severe asthma
Feb 26 AMGN Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
Feb 26 IONS Ionis Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
Feb 26 OPK Pfizer, OPKO Health's somatrogon application validated in Europe
Feb 26 SPPI Spectrum Pharmaceuticals Announces Poster Presentation at Upcoming Miami Breast Cancer Conference
Feb 26 EXEL Bristol Myers' opdivo combo wins positive opinion from EU in kidney cancer
Feb 26 EXEL Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Feb 26 CBLI INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - PAND, PRAH, AEGN, PTVCA, CRHM, CBLI, AKER
Feb 25 EPIX ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
Feb 25 INO A Balanced Take on Inovio Pharmaceuticals Stock
Feb 25 CRDF Cardiff Oncology EPS misses by $0.05, beats on revenue
Feb 25 ENDP Endo posts Q4 beat on Sterile Injectables strength
Feb 25 ENDP Endo EPS beats by $0.27, beats on revenue
Feb 25 PROF Profound Medical to Participate in March Virtual Investor Conferences
Feb 25 ENDP Endo Reports Fourth-Quarter And Full-Year 2020 Financial Results And Introduces 2021 Financial Guidance
Feb 25 EPIX ESSA Pharma to Present at Upcoming March Investor Conferences
Feb 25 CRDF Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

More about Prostate Cancer
Browse All Tags